LT3820873T - Selektyvūs estrogenų receptorių skaidytojai - Google Patents

Selektyvūs estrogenų receptorių skaidytojai

Info

Publication number
LT3820873T
LT3820873T LTEPPCT/US2019/041334T LTUS2019041334T LT3820873T LT 3820873 T LT3820873 T LT 3820873T LT US2019041334 T LTUS2019041334 T LT US2019041334T LT 3820873 T LT3820873 T LT 3820873T
Authority
LT
Lithuania
Prior art keywords
estrogen receptor
selective estrogen
receptor degraders
degraders
selective
Prior art date
Application number
LTEPPCT/US2019/041334T
Other languages
English (en)
Inventor
Jolie Anne Bastian
Jeffrey Daniel Cohen
Almudena RUBIO
Daniel Jon Sall
Jennifer Anne Mcmahon
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3820873(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT3820873T publication Critical patent/LT3820873T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Finger-Pressure Massage (AREA)
LTEPPCT/US2019/041334T 2018-07-12 2019-07-11 Selektyvūs estrogenų receptorių skaidytojai LT3820873T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
LT3820873T true LT3820873T (lt) 2023-01-10

Family

ID=67470734

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/041334T LT3820873T (lt) 2018-07-12 2019-07-11 Selektyvūs estrogenų receptorių skaidytojai

Country Status (36)

Country Link
US (4) US10654866B2 (lt)
EP (2) EP4155310A1 (lt)
JP (4) JP6995241B2 (lt)
KR (3) KR20230148386A (lt)
CN (2) CN117379428A (lt)
AR (1) AR115694A1 (lt)
AU (2) AU2019299947B2 (lt)
BR (2) BR112020025654A2 (lt)
CA (1) CA3105501C (lt)
CL (1) CL2021000045A1 (lt)
CO (1) CO2021000043A2 (lt)
CR (1) CR20210007A (lt)
DK (1) DK3820873T3 (lt)
EA (1) EA202092975A1 (lt)
EC (1) ECSP21001770A (lt)
ES (1) ES2933980T3 (lt)
FI (1) FI3820873T3 (lt)
HR (1) HRP20230009T1 (lt)
HU (1) HUE060963T2 (lt)
IL (3) IL280065B (lt)
JO (1) JOP20210005A1 (lt)
LT (1) LT3820873T (lt)
MA (2) MA53126B1 (lt)
MD (1) MD3820873T2 (lt)
MX (2) MX2021000375A (lt)
PE (1) PE20210400A1 (lt)
PH (1) PH12021550049A1 (lt)
PL (1) PL3820873T3 (lt)
PT (1) PT3820873T (lt)
RS (1) RS63809B1 (lt)
SA (1) SA521421008B1 (lt)
SG (1) SG11202100148TA (lt)
SI (1) SI3820873T1 (lt)
TW (1) TWI702219B (lt)
UA (1) UA127507C2 (lt)
WO (1) WO2020014435A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366996B (zh) 2015-10-01 2021-04-09 奥列马制药公司 四氢-1H-吡啶[3,4-b]吲哚类抗***药物
AU2019299952B2 (en) * 2018-07-12 2022-06-16 Eli Lilly And Company Selective estrogen receptor degraders
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性***受體降解劑
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
MX2023010394A (es) 2021-03-09 2023-09-14 Lilly Co Eli Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
TW202300492A (zh) * 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性***受體降解劑
US11926634B2 (en) * 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
JP2024067010A (ja) 2022-11-02 2024-05-16 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024105147A1 (en) 2022-11-17 2024-05-23 Astrazeneca Ab Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60210283T2 (de) * 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
NZ536291A (en) * 2002-04-19 2006-09-29 Signal Pharm Inc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
EP1709021B1 (en) * 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
MX2015016171A (es) * 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MA53837A (fr) 2014-12-18 2021-11-10 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations
EP3233828B1 (en) * 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
AU2019299952B2 (en) * 2018-07-12 2022-06-16 Eli Lilly And Company Selective estrogen receptor degraders
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性***受體降解劑

Also Published As

Publication number Publication date
US20230234960A1 (en) 2023-07-27
CR20210007A (es) 2021-02-08
KR102550538B1 (ko) 2023-07-04
PT3820873T (pt) 2022-12-23
CN117379428A (zh) 2024-01-12
CA3105501C (en) 2023-10-31
JP7241211B2 (ja) 2023-03-16
SA521421008B1 (ar) 2022-10-30
US10654866B2 (en) 2020-05-19
BR112020025654A2 (pt) 2021-04-06
SI3820873T1 (sl) 2023-02-28
IL295598B1 (en) 2023-05-01
PH12021550049A1 (en) 2021-09-20
CN112638916A (zh) 2021-04-09
US20210403480A1 (en) 2021-12-30
MD3820873T2 (ro) 2023-05-31
IL289871B (en) 2022-10-01
CN112638916B (zh) 2023-09-12
MA53124B1 (fr) 2023-02-28
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
EP4155310A1 (en) 2023-03-29
TW202019935A (zh) 2020-06-01
ES2933980T3 (es) 2023-02-15
RS63809B1 (sr) 2023-01-31
US20200347073A1 (en) 2020-11-05
AU2022203969A1 (en) 2022-06-30
ECSP21001770A (es) 2021-02-26
US11117902B2 (en) 2021-09-14
TWI702219B (zh) 2020-08-21
PL3820873T3 (pl) 2023-02-13
KR20230148386A (ko) 2023-10-24
JP2021530484A (ja) 2021-11-11
UA127507C2 (uk) 2023-09-13
JOP20210005A1 (ar) 2021-01-10
AU2019299947A1 (en) 2021-01-07
PE20210400A1 (es) 2021-03-02
KR20230005404A (ko) 2023-01-09
KR102589886B1 (ko) 2023-10-17
FI3820873T3 (fi) 2023-03-02
IL295598B2 (en) 2023-09-01
AU2019299947B2 (en) 2022-03-17
IL289871B2 (en) 2023-02-01
KR20210019065A (ko) 2021-02-19
HRP20230009T1 (hr) 2023-02-17
AR115694A1 (es) 2021-02-17
JP2022037102A (ja) 2022-03-08
SG11202100148TA (en) 2021-02-25
IL280065B (en) 2022-04-01
JP2023081954A (ja) 2023-06-13
BR122023025061A2 (pt) 2024-02-20
DK3820873T3 (da) 2022-12-12
WO2020014435A1 (en) 2020-01-16
JP2022050591A (ja) 2022-03-30
CO2021000043A2 (es) 2021-01-18
EP3820873B1 (en) 2022-11-23
AU2022203969B2 (en) 2024-02-15
IL289871A (en) 2022-03-01
EA202092975A1 (ru) 2021-04-14
JP7009672B1 (ja) 2022-01-25
EP3820873A1 (en) 2021-05-19
IL280065A (en) 2021-03-01
MA53126B1 (fr) 2023-02-28
CL2021000045A1 (es) 2021-07-19
HUE060963T2 (hu) 2023-04-28
IL295598A (en) 2022-10-01
US11634426B2 (en) 2023-04-25
MX2021000375A (es) 2021-05-27
MA53124A (fr) 2021-05-19
MA53126A (fr) 2021-05-19
JP6995241B2 (ja) 2022-01-14
CA3105501A1 (en) 2020-01-16
US20200017516A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL295598B2 (en) Selective estrogen receptor antagonists
ZA201805573B (en) Selective estrogen receptor degraders and uses thereof
IL285318A (en) Estrogen receptor modulators
IL279990B1 (en) Selective estrogen receptor antagonists
ZA202003023B (en) Benzothiophene-based selective estrogen receptor downregulators
IL268263A (en) Estrogen receptor modulators
ZA202201157B (en) Selective estrogen receptor degrader
EP3902545A4 (en) NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
PL3500265T3 (pl) Selektywne ligandy receptora estrogenowego beta